Post-Marketing Plans: An Often-Overlooked Component of FDA Advisory Committee Meeting Discussions

To request access to this content please complete the form below.

This article speaks to the importance of post-approval activities as part of the discussion and voting topics that the FDA will pose to the Advisory Committee.

Preparing effectively for an FDA Advisory Committee (ADCOM) meeting requires that the sponsor team anticipate the discussion and voting topics that the FDA will pose at the ADCOM meeting. Those discussion topics and voting questions will influence the information that the team provides to the ADCOM and the questions that the ADCOM poses to the team.

To that end, we compiled and reviewed all “final questions” posed at ADCOMs from 2010 through the first half of 2015. The analysis was limited to ADCOM meetings that considered the initial approval of a drug or device, or approval of additional indications. Questions pertaining to post-approval activities, typically safety assessments, were tabulated.

This study originally appeared in Regulatory Focus. Complete the form to view our complete results.

  • Share On

Recommended Posts

Webinar: CHMP OEs and FDA ADCOMs – Navigating the Differences to Prepare for Success

Want to Succeed at Your FDA Advisory Committee Meeting? Don’t Ignore the Power of a First Impression

Going Back to the Basics of Effective Communications – How Manufacturers Should Approach Medicare’s Drug Price Negotiation Program

Leveraging an Investigative Reporting Toolbox – An Untraditional Approach to Media Training

How Can We Help You?

Get Started